About

Compared with Tirzepatide injection version (eg. Zepbound, our product has these advantages: LESS PAIN – Without needle, SlimEase achieved 92% of patient adherence in a 6-months study.BETTER WEIGHT LOSS EFFECT – Mean weight loss of 20% in 36 weeks.EASIER TO USE – No cold chain needed for SlimEase is in tablet form.

The world's only dual-target agonist obesity treatment patients.

Clinical trial results showed an average weight loss of 20.9%

Revolutionary science redefines efficacy. It can activate GLP-1 and GIP receptors at the same time, effectively suppress appetite, enhance metabolic function, etc. Dual receptors double the efficacy and bring disruptive weight management.

Shopping Cart
Scroll to Top